In these videos we’ve been going through a series on the Teal stage of prostate cancer otherwise known as intermediate risk.  Intermediate risk or Teal carries a very broad spectrum even though it’s only one of the five stages.  Teal is broken down into Low, Basic, and High.  Today’s video is covering what we call combination therapy.  Combination therapy for prostate cancer consists of three things for Teal: a seed implant, testosterone inactivating pharmaceuticals (TIP) (otherwise known as androgen deprivation or testosterone blockade), and IMRT which stands for intensity modulating radiation.  These things are….

IMRT first came on the scene around 2004 and for the first time radiation therapy—beam radiation therapy—surpassed surgery as the preferred type of treatment.  Prior to that we had something called 3D conformal and it was somewhat effective, but unfortunately…

So in this video we are going to cover an important treatment for intermediate risk or Teal prostate cancer called High Dose Rate Temporary Seeds or “HDR.”  Seed implantation comes in two forms. You can look at our video on permanent seeds, which is the most popular type of…

Brachytherapy seeds will be the first in this series because in many ways in can be argued to be the best treatment or at least the best standard treatment for Teal.  Treatment for Teal involves a variety of comparisons…

In this video we’re going to cover a brief overview of the stage we call Teal.  Teal is a transition stage between harmless prostate cancer, which we call Sky, and consequential prostate cancer which we call Azure.  We break Teal into three sub-types: Low, Basic, and High. Low-Teal…

Hello Researcher, welcome to our fall issue of Prostate Digest. We recently held the 2018 Prostate Cancer Conference, and this issue has a summary of the event and information about how to get the event DVD. This issue contains four important articles covering new treatments and scans. The first highlights a recently FDA-approved oral medication called Earleada, which provided highly-effective therapy for men with hormone resistance. Our second articles reviews brachytherapy (seed implants) which are…

PCRI is grateful to everyone who attended our annual Prostate Cancer Conference, and we extend our thanks to all of the heroes who donate to ensure we can continue our mission. For those who were unable to attend, here is a recap of all of the wonderful information and events at the 2018 Prostate Cancer Conference. You can also order a DVD of the main sessions and Q+As at our website www.pcri.org

1. Always obtain and keep copies of your medical records.

2. Take things a step at a time and do your research. This is your life and your health, so you want to make the best decisions for yourself. Talk to your doctor about what you have researched, and don’t be afraid to do more research on treatments your doctor discusses with you.

In February 2018, the FDA approved Erleada for the treatment of prostate cancer. Erleada is an oral medicine approved for nonmetastatic, hormone-resistant disease. Men who have a rising PSA, low testosterone, and clear scans should begin Erleada immediately. Phase 3 SPARTAN clinical trial data showed that ERLEADA™ delays the  development of metastasis by over two years.

When your doctor gives you the results of your biopsy and tells you that you have cancer, many questions race through your mind. “Are you sure? How could I have cancer when I feel fine? Could this be a mistake?”